Gans,
Why?
After the recent CR they will have US$2.1 Billion in cash.
Their Exondys drug rakes in + US$500m revenue per year from 13% of DMD boys.
If ANP didn't have the additional indications - I would say a cash and scrip bid at some point down the future was possible before P2B was finished next year.
BUT with latest proteomics data on hand, we are aiming for the big league.
Best case would be non-exclusive DMD deals - that way - Pfizer, Roche, Solid and Capricor can play too.
Just like "Intel" is inside every PC.
ATL1102 will be inside every DMD therapeutic
All will be revealed soon.
...we might just end up with a small and lazy CR at 20c to get things started with EMA.
.
Where others have failed will Atl1102 succeed ?, page-587
-
- There are more pages in this discussion • 510 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
